Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Total body weight \>= 50 kg and body mass index (BMI) \>=18 kg/m2 and \<=35 kg/m2~* in good health with no history, or current evidence of clinically significant medical condition of laboratory, ECG or vital sign abnormality~* Sero suitable for challenge virus~Exclusion Criteria:~* History of or currently active symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to first study visit~* Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression),metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease~* females who are breastfeeding or have been pregnant within 6 months prior to the study or have a positive pregnancy test~* Lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction~* Any significant abnormality altering the anatomy of the nose in a substantial way~* Any clinically significant history of epistaxis (large nosebleeds)~* Any nasal or sinus surgery within 3 months of first study visit~* Evidence of vaccinations within 4 weeks of Day 0~* Receipt of blood or blood products, or loss of 550 mL or more blood within last 3 months~* Receipt of 3 or more investigational drug within last 12 months~* Prior inoculation with a virus from the same virus-family as the challenge~* Prior participation in another HVC study with a respiratory virus in last 3 months~* Use or anticipated use during the conduct of the study of protocol specified concomitant medications~* Systemic antiviral administration within 4 weeks of viral challenge~* Confirmed positive test for drugs of abuse~* History or presence of alcohol addiction, or excessive use of alcohol~* A forced expiratory volume in 1 second (FEV1) \<80%~* Positive HIV, hepatitis B virus, or hepatitis C virus test~* Presence of fever upto 2 days prior to Day 0.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active (Type: EXPERIMENTAL): spray-dried dispersion (SDD) for Oral Suspension
- Placebo (Type: PLACEBO_COMPARATOR): spray-dried dispersion (SDD) for Oral Suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).